Health Care & Life Sciences » Pharmaceuticals | C4X Discovery Holdings PLC

C4X Discovery Holdings PLC | Income Statement

Fiscal year is August-July. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
736.00
619.00
312.00
279.00
143.00
7,064
Cost of Goods Sold (COGS) incl. D&A
15.00
27.00
117.00
100.00
182.00
188
Gross Income
721.00
592.00
195.00
179.00
39.00
6,876
SG&A Expense
1,308.00
1,812.00
4,058.00
6,900.00
8,386.00
9,409
EBIT
587.00
1,220.00
3,863.00
6,721.00
8,425.00
2,533
Unusual Expense
-
-
-
68.00
68.00
-
Interest Expense
89.00
119.00
-
-
-
-
Pretax Income
676.00
1,338.00
3,814.00
6,757.00
8,490.00
2,526
Income Tax
195.00
220.00
750.00
1,436.00
1,708.00
1,391
Consolidated Net Income
481.00
1,118.00
3,064.00
5,321.00
6,782.00
1,135
Net Income
481.00
1,118.00
3,064.00
5,321.00
6,782.00
1,135
Net Income After Extraordinaries
481.00
1,118.00
3,064.00
5,321.00
6,782.00
1,135
Net Income Available to Common
481.00
1,118.00
3,064.00
5,321.00
6,782.00
1,135
EPS (Basic)
0.02
0.04
0.11
0.17
0.17
0.02
Basic Shares Outstanding
30,988.60
30,988.60
28,457.00
31,616.60
40,171.70
46,572.90
EPS (Diluted)
0.02
0.04
0.11
0.17
0.17
0.02
Diluted Shares Outstanding
30,988.60
30,988.60
28,457.00
31,616.60
40,171.70
46,572.90
EBITDA
573.00
1,207.00
3,837.00
6,633.00
8,246.00
2,345
Non-Operating Interest Income
-
1.00
49.00
32.00
3.00
7

About C4X Discovery Holdings

View Profile
Address
Manchester One
Manchester Greater Manchester M1 3LD
United Kingdom
Employees -
Website http://c4xdiscovery.com/
Updated 07/08/2019
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. Its software platforms consists of Taxonomy3, which utilizes a mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases; and Conformetrix, which determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.